Catalysts
CYTK Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
CYTKCytokinetics, Incorporated
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum28
- Value41
- Quality46
- Risk resilience56
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 28/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 26.22%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | — | -$1.43 | -$1.37 | +4.2% | $41.88M | $47.56M |
| Aug 6, 2026 | — | -$1.63 | -$1.50 | +8.0% | $17.59M | $28.62M |
| May 5, 2026 | — | -$1.67 | -$1.67 | +0.0% | $8.52M | $19.36M |
| Feb 24, 2026 | — | -$1.48 | -$1.50 | -1.4% | $6.93M | $17.76M |
| Nov 5, 2025 | — | -$1.59 | -$2.55 | -60.4% | $6.05M | $1.94M |
| Aug 7, 2025 | — | -$1.34 | -$1.12 | +16.4% | $2.07M | $66.77M |
| May 6, 2025 | — | -$1.41 | -$1.36 | +3.5% | $2.79M | $1.58M |
| Feb 27, 2025 | — | -$1.29 | -$1.26 | +2.3% | $14.26M | $16.93M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved...
Related Links
CYTK Catalysts FAQ
What are the next catalysts for CYTK stock?
CYTK's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move CYTK stock?
Upcoming events that could move CYTK include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could CYTK's next earnings report affect the stock?
CYTK's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive CYTK stock higher?
CYTK could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt CYTK stock?
CYTK could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.